| Literature DB >> 35656374 |
Huan Yu1, Chao Ni1, Yuhan Xia1, Jie Li1, Biyao Hang1, Cheng Han2, Zhipeng Xu1, Ming Luo1, Xing Rong1, Jinshun Zhu1, Maoping Chu1.
Abstract
Background: Kawasaki disease (KD) is an acute febrile systemic vasculitis of unknown etiology. After the pandemic of coronavirus disease 2019 (COVID-19), some children infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) showed clinical symptoms similar to KD, indicating a close relationship between KD and SARS-CoV-2. Therefore, we designed this retrospective study to analyze the characteristics of KD patients before and after the COVID-19 pandemic.Entities:
Keywords: CALs; COVID-19; Kawasaki; age; albumin; hospitalization
Year: 2022 PMID: 35656374 PMCID: PMC9152138 DOI: 10.3389/fped.2022.895408
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
Demographic and clinical characteristics.
|
|
|
|
|
|---|---|---|---|
| Male (%) | 138 (62.2%) | 228 (64%) | 0.658 |
| Age (month) | 25.55 ± 25.22 | 29.14 ± 22.27 | 0.002 |
| IKD (%) | 80 (36%) | 103 (28.9%) | 0.081 |
| IVIG-R (%) | 13 (5.9%) | 21 (5.9%) | 1 |
| Hosday (days) | 7.06 ± 3.28 | 7.44 ± 3.19 | 0.024 |
| HB (g/L) | 111.87 ± 13.14 | 112.66 ± 9.68 | 0.682 |
| PLT (×1012) | 367.30 ± 151.37 | 371.21 ± 127.63 | 0.335 |
| WBC (×1012) | 15.93 ± 9.72 | 15.83 ± 6.29 | 0.315 |
| N (×1012) | 10.08 ± 4.91 | 10.92 ± 5.36 | 0.032 |
| L (×1012) | 3.76 ± 2.04 | 3.43 ± 2.12 | 0.023 |
| E (×1012) | 0.44 ± 0.67 | 0.39 ± 0.42 | 0.253 |
| HCT (%) | 0.35 ± 0.27 | 0.34 ± 0.28 | 0.69 |
| CRP (mg/dl) | 83.85 ± 53.58 | 91.68 ± 59.65 | 0.179 |
| ESR (mm/h) | 38.84 ± 17.34 | 45.68 ± 18.49 | <0.001 |
| Na (mmol/L) | 135.51 ± 2.39 | 135.26 ± 2.42 | 0.237 |
| K (mmol/L) | 4.41 ± 0.59 | 4.37 ± 0.51 | 0.103 |
| Cl (mmol/L) | 101.8 ± 2.64 | 101.19 ± 2.85 | 0.012 |
| Ca (mmol/L) | 2.31 ± 0.14 | 3.35 ± 0.13 | <0.001 |
| Mg (mmol/L) | 0.88 ± 0.12 | 0.90 ± 0.09 | 0.007 |
| P (mmol/L) | 1.39 ± 0.27 | 1.40 ± 0.27 | 0.926 |
| ALT (U/L) | 71.83 ± 111.92 | 80.05 ± 113.59 | 0.062 |
| AST (U/L) | 73.30 ± 117.17 | 66.34 ± 118.77 | 0.197 |
| ALB (g/L) | 41.00 ± 5.66 | 39.67 ± 4.02 | 0.001 |
| GGT (U/L) | 72.42 ± 99.44 | 76.45 ± 89.24 | 0.06 |
| TBIL (umol/L) | 10.66 ± 11.36 | 10.83 ± 14.25 | 0.201 |
| DBIL (umol/L) | 3.96 ± 6.68 | 4.09 ± 8.00 | 0.493 |
| IBIL (umol/L) | 5.43 ± 4.26 | 5.39 ± 4.81 | 0.932 |
IKD, incomplete Kawasaki disease; IVIG-R, intravenous immunoglobulin-resistance; HB, hemoglobin; PLT, platelets; WBC, white blood cell; N, neutrophils; L, lymphocyte; E, eosinophil; HCT, hematocrit; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; Na, sodium; K, potassium; Cl, chlorine; Ca, calcium; Mg, magnesium; P, phosphorus; ALT, aspartate aminotransferase; AST, alanine aminotransferase; ALB, albumin; GGT, gamma glutamate transferase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.
p < 0.05.
Demographic and clinical characteristics.
|
|
|
|
|
|---|---|---|---|
| Male (%) | 138 (62.2%) | 945 (64.3%) | 0.549 |
| Age (month) | 25.69 ± 25.59 | 27.41 ± 22.37 | 0.022 |
| IKD (%) | 80 (36%) | 387 (26.3%) | 0.004 |
| IVIG-R (%) | 13 (5.9%) | 91 (6.1%) | 1 |
| Hosday (days) | 7.12 ± 3.32 | 8.34 ± 3.36 | <0.001 |
| HB (g/L) | 111.92 ± 13.28 | 112.11 ± 10.38 | 0.338 |
| PLT (×1012) | 368.76 ± 152.85 | 378.84 ± 129.19 | 0.086 |
| WBC (×1012) | 15.42 ± 7.00 | 15.93 ± 5.77 | 0.033 |
| N (×1012) | 9.96 ± 4.92 | 10.86 ± 5.02 | 0.003 |
| L (×1012) | 3.81 ± 2.04 | 3.71 ± 2.15 | 0.288 |
| E (×1012) | 0.44 ± 0.69 | 0.39 ± 0.45 | 0.134 |
| HCT (%) | 0.35 ± 0.27 | 0.34 ± 0.31 | 0.45 |
| CRP (mg/dl) | 81.40 ± 52.22 | 85.18 ± 56.88 | 0.481 |
| ESR (mm/h) | 38.64 ± 17.53 | 37.4 ± 15.25 | 0.185 |
| Na (mmol/L) | 135.54 ± 2.37 | 135.60 ± 2.57 | 0.76 |
| K (mmol/L) | 4.42 ± 0.58 | 4.33 ± 0.55 | 0.015 |
| Cl (mmol/L) | 101.90 ± 2.62 | 101.05 ± 2.84 | <0.001 |
| Ca (mmol/L) | 2.31 ± 0.14 | 2.32 ± 0.13 | 0.311 |
| Mg (mmol/L) | 0.89 ± 0.12 | 0.91 ± 0.10 | <0.001 |
| P (mmol/L) | 1.40 ± 0.27 | 1.39 ± 0.27 | 0.603 |
| ALT (U/L) | 70.68 ± 111.00 | 77.12 ± 106.96 | 0.01 |
| AST (U/L) | 73.60 ± 119.15 | 59.21 ± 94.58 | 0.021 |
| ALB (g/L) | 40.91 ± 5.16 | 39.78 ± 4.02 | <0.001 |
| GGT (U/L) | 70.76 ± 97.75 | 82.25 ± 96.99 | 0.005 |
| TBIL (umol/L) | 10.48 ± 11.28 | 9.51 ± 11.56 | 0.013 |
| DBIL (umol/L) | 3.76 ± 6.45 | 3.63 ± 6.65 | 0.138 |
| IBIL (umol/L) | 5.29 ± 4.22 | 5.16 ± 4.78 | 0.658 |
IKD, incomplete Kawasaki disease; IVIG-R, intravenous immunoglobulin-resistance; HB, hemoglobin; PLT, platelets; WBC, white blood cell; N, neutrophils; L, lymphocyte; E, eosinophil; HCT, hematocrit; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; Na, sodium; K, potassium; Cl, chlorine; Ca, calcium; Mg, magnesium; P, phosphorus; ALT, aspartate aminotransferase; AST, alanine aminotransferase; ALB, albumin; GGT, gamma glutamate transferase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.
p < 0.05.
Demographic and clinical characteristics.
|
|
|
|
|
|---|---|---|---|
| Male (%) | 38 (56.7%) | 100 (64.5%) | 0.294 |
| Age (month) | 33.48 ± 30.30 | 22.32 ± 22.56 | 0.003 |
| IKD (%) | 16 (23.9%) | 64 (41.3%) | 0.015 |
| IVIG-R (%) | 6 (9.0%) | 7 (4.5%) | 0.217 |
| Hosday (days) | 6.37 ± 3.05 | 7.44 ± 3.38 | 0.001 |
| HB (g/L) | 115.33 ± 11.34 | 110.44 ± 13.82 | 0.008 |
| PLT (×1012) | 349.10 ± 118.41 | 377.31 ± 165.23 | 0.492 |
| WBC (×1012) | 17.02 ± 8.94 | 14.72 ± 5.86 | 0.029 |
| N (×1012) | 11.11 ± 4.97 | 9.46 ± 4.83 | 0.004 |
| L (×1012) | 3.76 ± 2.04 | 3.71 ± 2.15 | 0.288 |
| E (×1012) | 0.44 ± 0.67 | 0.39 ± 0.45 | 0.134 |
| HCT (%) | 0.40 ± 0.49 | 0.33 ± 0.03 | 0.044 |
| CRP (mg/dl) | 85.09 ± 45.73 | 79.8 ± 54.87 | 0.187 |
| ESR (mm/h) | 37.38 ± 14.19 | 39.23 ± 18.9 | 0.459 |
| Na (mmol/L) | 135.12 ± 1.86 | 135.73 ± 2.55 | 0.024 |
| K (mmol/L) | 4.35 ± 0.48 | 4.45 ± 0.62 | 0.16 |
| Cl (mmol/L) | 101.00 ± 2.26 | 102.30 ± 2.68 | 0.001 |
| Ca (mmol/L) | 2.28 ± 0.13 | 2.33 ± 0.14 | 0.017 |
| Mg (mmol/L) | 0.88 ± 0.14 | 0.89 ± 0.11 | 0.544 |
| P (mmol/L) | 1.37 ± 0.24 | 1.42 ± 0.28 | 0.187 |
| ALT (U/L) | 82.39 ± 146.86 | 65.55 ± 91.11 | 0.98 |
| AST (U/L) | 84.16 ± 166.85 | 68.48 ± 87.57 | 0.858 |
| ALB (g/L) | 41.06 ± 4.78 | 40.84 ± 5.33 | 0.389 |
| GGT (U/L) | 76.57 ± 111.15 | 67.80 ± 90.58 | 0.005 |
| TBIL (umol/L) | 9.80 ± 8.51 | 10.78 ± 12.32 | 0.804 |
| DBIL (umol/L) | 3.54 ± 5.18 | 3.87 ± 7.00 | 0.881 |
| IBIL (umol/L) | 5.37 ± 3.64 | 5.26 ± 4.49 | 0.37 |
IKD, incomplete Kawasaki disease; IVIG-R, intravenous immunoglobulin-resistance; HB, hemoglobin; PLT, platelets; WBC, white blood cell; N, neutrophils; L, lymphocyte; E, eosinophil; HCT, hematocrit; CRP, c-reactive protein; ESR, erythrocyte sedimentation rate; Na, sodium; K, potassium; Cl, chlorine; Ca, calcium; Mg, magnesium; P, phosphorus; ALT, aspartate aminotransferase; AST, alanine aminotransferase; ALB, albumin; GGT, gamma glutamate transferase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin.
p < 0.05.
The comparision of CAL incidence.
|
|
|
| |
|---|---|---|---|
| CAL before treatment | 470 (32.0%) | 61 (27.5%) | 105 (29.5%) |
| CAL after treatment | 454 (30.9%) | 59 (26.6%) | 99 (27.8%) |
CAL was defined as mentioned in the article. CAL before treatment means that CAL was calculated before treatment with IVIG to the end of follow-up. CAL after treatment means that CAL was calculated after treatment with IVIG to the end of follow-up. Patients who had a CAL at any time during the study period were counted. *P < 0.05.
Figure 1Characteristics of ages before and after the COVID-19 pandemic.
Figure 3Characteristics of albumin before and after the COVID-19 pandemic.
The comparision between different ages.
|
|
|
|
|
|---|---|---|---|
| ≤1y | 392 (26.7%) | 79 (35.6%) | 0.022 |
| 1–5y | 939 (63.9%) | 125 (56.3%) | |
| >5y | 139 (9.5%) | 18 (8.1%) |
Comparison between different ages among patients enrolled from 2015 to 2019 and patients admitted in 2020.
P < 0.05.
The comparision between different ages.
|
|
|
|
|
|---|---|---|---|
| ≤1y | 79 (22.2%) | 79 (35.6%) | 0.002 |
| 1–5y | 240 (67.4%) | 125 (56.3%) | |
| >5y | 37 (10.4%) | 18 (8.1%) |
Comparison between different ages among patients enrolled in 2019 and patients admitted in 2020.
P < 0.05.
The comparision between different ages.
|
|
|
|
|
|---|---|---|---|
| ≤1y | 19 (28.4%) | 60 (38.7%) | 0.032 |
| 1–5y | 38 (56.7%) | 87 (56.1%) | |
| >5y | 10 (14.9%) | 8 (5.2%) |
Comparison between different ages among patients enrolled from January to March 2020 and patients admitted from April to December 2020.
P < 0.05.